Canada approves GSK's Hibsago for chronic hepatitis B
Health Canada authorized Hibsago (bepirovirsen) for chronic hepatitis B.
Related stories
Liberty Global Returns to Profit in Q3 2026
Liberty Global returned to profitability in Q3 2026.
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC
Sysco Reports Higher Q1 FY27 Net Profit and Revenue
Sysco reported year-over-year increases in net profit and revenue in Q1 FY27.
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC
Ardmore Shipping Q3 Revenue Beats Estimates on Higher Spot Charter Rates
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC
PJT Partners Reports Q3 Adjusted Earnings; Revenue Falls
PJT Partners reported Q3 adjusted earnings, and revenue fell.
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC
Advanced Info Service Reports Quarterly Attributable Profit of 13.50 Billion Baht
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC
Sysco Reports Fiscal Q1 Profit
Sysco reported fiscal first-quarter profit, according to The Associated Press. The amount was not provided in the available text.
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC